Corbus Pharmaceuticals Highlights Data From Its First US-Based Trial Of Lead Cancer Drug Candidate
Corbus Pharmaceuticals presented Phase 1 data on CRB-701 at ASCO GU, showing safety, tolerability, and responses across multiple tumor types.
What is HC Wainwright’s Forecast for CRBP FY2029 Earnings?
Analysts at HC Wainwright issued their FY2029 earnings estimates for shares of Corbus Pharmaceuticals in a note issued to investors on Monday, February 10th. HC Wainwright analyst A. Maldonado expects ...
SuperSport16h
Threepeat-chasing Pirates look to avoid Baroka upset
Orlando Pirates will continue their defence of the Nedbank Cup by facing Baroka FC in the Round of 16 encounter at the ...
Corbus Pharmaceuticals falls after trial data for lead asset
Corbus Pharmaceuticals (CRBP) stock drops 12% after mixed Phase 1 trial results for its lead cancer candidate. Read more here.
RBC Capital Sticks to Its Buy Rating for Corbus Pharmaceuticals (CRBP)
In a report released on February 11, Brian Abrahams from RBC Capital maintained a Buy rating on Corbus Pharmaceuticals (CRBP – Research ...
Cam Newton doubles down on saying Panthers had ‘locker room of losers’ prior to drafting him
Former Carolina star quarterback Cam Newton doubled down on recent comments that the Panthers had “a locker room of losers” ...